Research Library — Pipeline Candidates | Reta Compare
16 research articles in Pipeline Candidates. Page 1 of 1.
Articles
- HM15275 (Hanmi): Quad-Agonist Candidate for Obesity
- HRS-7535 (Hengrui): An Oral Small-Molecule Multi-Receptor Agonist for Obesity and Metabolic Disorders
- IBI-3034 (Innovent): Advancing the Triple and Quad Agonist Pipeline from China
- Eli Lilly's Post-Retatrutide Pipeline: Future Directions Beyond LY3437943
- Novo Nordisk's Post-Semaglutide Pipeline: Amycretin and Future Multi-Agonists
- Boehringer Ingelheim Survodutide and the Path Toward Quad-Agonists
- Pfizer's Multi-Agonist Obesity Pipeline
- AstraZeneca and Eccogene: Oral GLP-1 and Future Multi-Agonists
- Roche's CT-388 and the Future of Dual and Triple Agonists
- Amgen MariTide (AMG 133): A Unique GLP-1 Agonist with GIP Antagonism
- Viking Therapeutics VK2735: A Dual GLP-1/GIP Agonist with Potential for Triple Action
- Structure Therapeutics GSBR-1290: Oral GLP-1 With Pipeline Expansion
- Altimmune Pemvidutide: GLP-1/Glucagon Dual Focused on NASH
- Sun Pharma's Utreglutide: Long-Acting GLP-1 with Pipeline Expansion
- Zealand Pharma's Petrelintide: An Amylin Analog Paving the Way for Quad Combinations
- Gubra Pipeline: GUBamy and the Future of Amylin and Incretin-Based Therapies